Skip to main content
Erschienen in: World Journal of Surgery 7/2012

01.07.2012

Resection of Pulmonary Metastases from Hepatocellular Carcinoma following Liver Transplantation

verfasst von: Shin Hwang, Yong-Hee Kim, Dong Kwan Kim, Chul-Soo Ahn, Deog-Bok Moon, Ki-Hun Kim, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Hyeong Ryul Kim, Gil-Chun Park, Jeong-Man Namgoong, Sam-Youl Yoon, Sung-Won Jung, Seung Il Park, Sung-Gyu Lee

Erschienen in: World Journal of Surgery | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

This study was intended to assess the effect of resection of pulmonary metastasis (PM) of hepatocellular carcinoma (HCC) after liver transplantation (LT). No effective treatment modality exists for PM-HCC, and little is known about the posttransplant outcomes of pulmonary metastasectomy (PMT).

Methods

Of 587 adult LT recipients diagnosed with HCC, 43 had PM-HCC. We retrospectively compared outcomes in 23 patients who underwent PMT and 20 who did not. PMT was precluded in ten patients in the non-PMT group by multiple (usually ≥5) lung nodules, in nine by lung nodules with concurrent or residual extrapulmonary metastasis, and in one by comorbidity.

Results

Of the 23 patients in the PMT group, 14 underwent a single session of PMT, 7 underwent 2 sessions each, and 2 underwent 3 sessions each, for a total of 34 sessions. There were no surgery-related deaths or complications. After first PMT, 41 nodules, each 0.2–2.5 cm in diameter, were observed: 1–5 nodules per patient. Every available treatment was provided to patients with post-PMT recurrence and those in the non-PMT group to control pulmonary and extrapulmonary metastases. Patient survival rates before PM diagnosis did not differ between the two groups (p = 0.141). However, 2 year post-PM survival rate was significantly greater in the PMT group (30.6% vs. 0%, p = 0.007), resulting in a significantly greater overall 5 year survival rate (44.7% vs. 12.8%, p = 0.017). Univariate analysis showed no risk factor significantly associated with patient survival after PMT.

Conclusions

PMT should be performed for resectable PM-HCC because it may provide a chance of long-term survival.
Literatur
1.
Zurück zum Zitat Hwang S, Lee SG, Belghiti J (2010) Liver transplantation for HCC: its role: Eastern and Western perspectives. J Hepatobiliary Pancreat Sci 17:443–448PubMedCrossRef Hwang S, Lee SG, Belghiti J (2010) Liver transplantation for HCC: its role: Eastern and Western perspectives. J Hepatobiliary Pancreat Sci 17:443–448PubMedCrossRef
2.
Zurück zum Zitat Lee S, Ahn C, Ha T, Moon D et al (2010) Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Sci 17:539–547PubMedCrossRef Lee S, Ahn C, Ha T, Moon D et al (2010) Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Sci 17:539–547PubMedCrossRef
3.
Zurück zum Zitat Hwang S, Moon DB, Lee SG (2010) Liver transplantation and conventional surgery for advanced hepatocellular carcinoma. Transpl Int 23:723–727PubMedCrossRef Hwang S, Moon DB, Lee SG (2010) Liver transplantation and conventional surgery for advanced hepatocellular carcinoma. Transpl Int 23:723–727PubMedCrossRef
4.
Zurück zum Zitat Todo S, Furukawa H, Japanese Study Group on Organ Transplantation (2004) Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 240:451–459PubMedCrossRef Todo S, Furukawa H, Japanese Study Group on Organ Transplantation (2004) Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 240:451–459PubMedCrossRef
5.
Zurück zum Zitat Lee SG, Hwang S, Moon DB et al (2008) Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 14:935–945PubMedCrossRef Lee SG, Hwang S, Moon DB et al (2008) Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 14:935–945PubMedCrossRef
6.
Zurück zum Zitat Chen F, Sato K, Fujinaga T et al (2008) Pulmonary resection for metastases from hepatocellular carcinoma. World J Surg 32:2213–2217PubMedCrossRef Chen F, Sato K, Fujinaga T et al (2008) Pulmonary resection for metastases from hepatocellular carcinoma. World J Surg 32:2213–2217PubMedCrossRef
7.
Zurück zum Zitat Kawamura M, Nakajima J, Matsuguma H et al (2008) Surgical outcomes for pulmonary metastases from hepatocellular carcinoma. Eur J Cardiothorac Surg 34:196–199PubMedCrossRef Kawamura M, Nakajima J, Matsuguma H et al (2008) Surgical outcomes for pulmonary metastases from hepatocellular carcinoma. Eur J Cardiothorac Surg 34:196–199PubMedCrossRef
8.
Zurück zum Zitat Kwon JB, Park K, Kim YD et al (2008) Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors. World J Gastroenterol 14:5717–5722PubMedCrossRef Kwon JB, Park K, Kim YD et al (2008) Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors. World J Gastroenterol 14:5717–5722PubMedCrossRef
9.
Zurück zum Zitat Lee CY, Bae MK, Park IK et al (2010) Surgical resection for pulmonary metastasis from hepatocellular carcinoma: analysis of prognosis in relation to primary control. J Surg Oncol 101:239–243PubMed Lee CY, Bae MK, Park IK et al (2010) Surgical resection for pulmonary metastasis from hepatocellular carcinoma: analysis of prognosis in relation to primary control. J Surg Oncol 101:239–243PubMed
10.
Zurück zum Zitat Yoon YS, Kim HK, Kim J et al (2010) Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 17:2795–2801PubMedCrossRef Yoon YS, Kim HK, Kim J et al (2010) Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 17:2795–2801PubMedCrossRef
11.
Zurück zum Zitat Han KN, Kim YT, Yoon JH et al (2010) Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma. Lung Cancer 70:295–300PubMedCrossRef Han KN, Kim YT, Yoon JH et al (2010) Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma. Lung Cancer 70:295–300PubMedCrossRef
12.
Zurück zum Zitat Kitano K, Murayama T, Sakamoto M et al (2011) Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg (in press) Kitano K, Murayama T, Sakamoto M et al (2011) Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg (in press)
13.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699PubMedCrossRef Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699PubMedCrossRef
14.
Zurück zum Zitat Hwang S, Ahn CS, Kim KH et al (2011) Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation. J Gastrointest Surg 15:971–981PubMedCrossRef Hwang S, Ahn CS, Kim KH et al (2011) Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation. J Gastrointest Surg 15:971–981PubMedCrossRef
15.
Zurück zum Zitat Lee JW, Paeng JC, Kang KW et al (2009) Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50:682–687PubMedCrossRef Lee JW, Paeng JC, Kang KW et al (2009) Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50:682–687PubMedCrossRef
16.
Zurück zum Zitat Kim YK, Lee KW, Cho SY et al (2010) Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl 16:767–772PubMedCrossRef Kim YK, Lee KW, Cho SY et al (2010) Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl 16:767–772PubMedCrossRef
17.
Zurück zum Zitat Yoon DH, Ryoo BY, Ryu MH et al (2010) Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 40:768–773PubMedCrossRef Yoon DH, Ryoo BY, Ryu MH et al (2010) Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 40:768–773PubMedCrossRef
18.
Zurück zum Zitat Toso C, Merani S, Bigam DL et al (2010) Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 51:1237–1243PubMedCrossRef Toso C, Merani S, Bigam DL et al (2010) Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 51:1237–1243PubMedCrossRef
19.
Zurück zum Zitat Schwarz RE, Abou-Alfa GK, Geschwind JF et al (2010) Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 12:313–320 Schwarz RE, Abou-Alfa GK, Geschwind JF et al (2010) Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 12:313–320
20.
Zurück zum Zitat Kim R, El-Gazzaz G, Tan A, Elson P et al (2010) Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 79:62–66PubMedCrossRef Kim R, El-Gazzaz G, Tan A, Elson P et al (2010) Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 79:62–66PubMedCrossRef
21.
Zurück zum Zitat Hwang S, Lee SG, Ahn CS et al (2010) A clinical assessment of mycophenolate drug monitoring after liver transplantation. Clin Transplant 24:E35–E42PubMedCrossRef Hwang S, Lee SG, Ahn CS et al (2010) A clinical assessment of mycophenolate drug monitoring after liver transplantation. Clin Transplant 24:E35–E42PubMedCrossRef
22.
Zurück zum Zitat Hwang S, Lee SG, Ahn CS et al (2008) Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl 14:770–778PubMedCrossRef Hwang S, Lee SG, Ahn CS et al (2008) Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl 14:770–778PubMedCrossRef
23.
Zurück zum Zitat Yi NJ, Suh KS, Cho JY et al (2007) Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 13:451–458PubMedCrossRef Yi NJ, Suh KS, Cho JY et al (2007) Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 13:451–458PubMedCrossRef
24.
Zurück zum Zitat Faria LC, Gigou M, Roque-Afonso AM et al (2008) Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134:1890–1899PubMedCrossRef Faria LC, Gigou M, Roque-Afonso AM et al (2008) Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134:1890–1899PubMedCrossRef
25.
Zurück zum Zitat Pang RW, Poon RT (2007) From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72(Suppl 1):30–44PubMedCrossRef Pang RW, Poon RT (2007) From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72(Suppl 1):30–44PubMedCrossRef
26.
Zurück zum Zitat Schwartz M, Roayaie S, Llovet J (2005) How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 43:584–589PubMedCrossRef Schwartz M, Roayaie S, Llovet J (2005) How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 43:584–589PubMedCrossRef
27.
Zurück zum Zitat Poon RT, Fan ST, O’Suilleabhain CB et al (2002) Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg 195:311–318PubMedCrossRef Poon RT, Fan ST, O’Suilleabhain CB et al (2002) Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg 195:311–318PubMedCrossRef
28.
Zurück zum Zitat Kothary N, Bartos JA, Hwang GL et al (2010) Computed tomography-guided percutaneous needle biopsy of indeterminate pulmonary pathology: efficacy of obtaining a diagnostic sample in immunocompetent and immunocompromised patients. Clin Lung Cancer 11:251–256PubMedCrossRef Kothary N, Bartos JA, Hwang GL et al (2010) Computed tomography-guided percutaneous needle biopsy of indeterminate pulmonary pathology: efficacy of obtaining a diagnostic sample in immunocompetent and immunocompromised patients. Clin Lung Cancer 11:251–256PubMedCrossRef
29.
Zurück zum Zitat Ng YL, Patsios D, Roberts H et al (2008) CT-guided percutaneous fine-needle aspiration biopsy of pulmonary nodules measuring 10 mm or less. Clin Radiol 63:272–277PubMedCrossRef Ng YL, Patsios D, Roberts H et al (2008) CT-guided percutaneous fine-needle aspiration biopsy of pulmonary nodules measuring 10 mm or less. Clin Radiol 63:272–277PubMedCrossRef
30.
Zurück zum Zitat Lee YT, Hwang S, Lee SG et al (2010) Living-donor liver transplantation in patients with concurrent active tuberculosis at transplantation. Int J Tuberc Lung Dis 14:1039–1044PubMed Lee YT, Hwang S, Lee SG et al (2010) Living-donor liver transplantation in patients with concurrent active tuberculosis at transplantation. Int J Tuberc Lung Dis 14:1039–1044PubMed
31.
Zurück zum Zitat Yeganeh M, Finn RS, Saab S (2009) Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 9:2851–2854PubMedCrossRef Yeganeh M, Finn RS, Saab S (2009) Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 9:2851–2854PubMedCrossRef
32.
Zurück zum Zitat Hata M, Tokuuye K, Sugahara S et al (2007) Proton beam therapy for aged patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 69:805–812PubMedCrossRef Hata M, Tokuuye K, Sugahara S et al (2007) Proton beam therapy for aged patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 69:805–812PubMedCrossRef
33.
Zurück zum Zitat Li C, Zhang F, Zhang W et al (2010) Feasibility of (125) I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol 136:1633–1640PubMedCrossRef Li C, Zhang F, Zhang W et al (2010) Feasibility of (125) I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol 136:1633–1640PubMedCrossRef
34.
Zurück zum Zitat Kim TS, Lim HK, Lee KS et al (2003) Imaging-guided percutaneous radiofrequency ablation of pulmonary metastatic nodules caused by hepatocellular carcinoma: preliminary experience. AJR Am J Roentgenol 181:491–494PubMed Kim TS, Lim HK, Lee KS et al (2003) Imaging-guided percutaneous radiofrequency ablation of pulmonary metastatic nodules caused by hepatocellular carcinoma: preliminary experience. AJR Am J Roentgenol 181:491–494PubMed
35.
Zurück zum Zitat Tomimaru Y, Sasaki Y, Yamada T et al (2006) The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma. Am J Surg 192:46–51PubMedCrossRef Tomimaru Y, Sasaki Y, Yamada T et al (2006) The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma. Am J Surg 192:46–51PubMedCrossRef
36.
Zurück zum Zitat Nakagawa T, Kamiyama T, Nakanishi K et al (2006) Pulmonary resection for metastases from hepatocellular carcinoma: factors influencing prognosis. J Thorac Cardiovasc Surg 131:1248–1254PubMedCrossRef Nakagawa T, Kamiyama T, Nakanishi K et al (2006) Pulmonary resection for metastases from hepatocellular carcinoma: factors influencing prognosis. J Thorac Cardiovasc Surg 131:1248–1254PubMedCrossRef
Metadaten
Titel
Resection of Pulmonary Metastases from Hepatocellular Carcinoma following Liver Transplantation
verfasst von
Shin Hwang
Yong-Hee Kim
Dong Kwan Kim
Chul-Soo Ahn
Deog-Bok Moon
Ki-Hun Kim
Tae-Yong Ha
Gi-Won Song
Dong-Hwan Jung
Hyeong Ryul Kim
Gil-Chun Park
Jeong-Man Namgoong
Sam-Youl Yoon
Sung-Won Jung
Seung Il Park
Sung-Gyu Lee
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 7/2012
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-012-1533-0

Weitere Artikel der Ausgabe 7/2012

World Journal of Surgery 7/2012 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.